|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 24565 |
FusionGeneSummary for NOL9_SUPT5H |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: NOL9_SUPT5H | Fusion gene ID: 24565 | Hgene | Tgene | Gene symbol | NOL9 | SUPT5H | Gene ID | 79707 | 6829 |
| Gene name | nucleolar protein 9 | SPT5 homolog, DSIF elongation factor subunit | |
| Synonyms | Grc3|NET6 | SPT5|SPT5H|Tat-CT1 | |
| Cytomap | 1p36.31 | 19q13.2 | |
| Type of gene | protein-coding | protein-coding | |
| Description | polynucleotide 5'-hydroxyl-kinase NOL9polynucleotide 5'-kinase | transcription elongation factor SPT5DRB sensitivity-inducing factor 160 kDa subunitDRB sensitivity-inducing factor large subunitDSIF large subunitDSIF p160Tat-cotransactivator 1 proteinhSPT5suppressor of Ty 5 homolog | |
| Modification date | 20180523 | 20180523 | |
| UniProtAcc | Q5SY16 | O00267 | |
| Ensembl transtripts involved in fusion gene | ENST00000377705, | ENST00000599117, ENST00000432763, ENST00000402194, ENST00000359191, ENST00000598725, | |
| Fusion gene scores | * DoF score | 4 X 4 X 5=80 | 7 X 6 X 4=168 |
| # samples | 5 | 7 | |
| ** MAII score | log2(5/80*10)=-0.678071905112638 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(7/168*10)=-1.26303440583379 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: NOL9 [Title/Abstract] AND SUPT5H [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | SUPT5H | GO:0000122 | negative regulation of transcription by RNA polymerase II | 9450929 |
| Tgene | SUPT5H | GO:0006368 | transcription elongation from RNA polymerase II promoter | 9450929 |
| Tgene | SUPT5H | GO:0032785 | negative regulation of DNA-templated transcription, elongation | 9450929 |
| Tgene | SUPT5H | GO:0032786 | positive regulation of DNA-templated transcription, elongation | 9450929 |
| Tgene | SUPT5H | GO:0045944 | positive regulation of transcription by RNA polymerase II | 9450929 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS3.1 | BF825716 | NOL9 | chr1 | 6592107 | + | SUPT5H | chr19 | 39960799 | + |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-3CDS | ENST00000377705 | ENST00000599117 | NOL9 | chr1 | 6592107 | + | SUPT5H | chr19 | 39960799 | + |
| intron-3CDS | ENST00000377705 | ENST00000432763 | NOL9 | chr1 | 6592107 | + | SUPT5H | chr19 | 39960799 | + |
| intron-3CDS | ENST00000377705 | ENST00000402194 | NOL9 | chr1 | 6592107 | + | SUPT5H | chr19 | 39960799 | + |
| intron-3CDS | ENST00000377705 | ENST00000359191 | NOL9 | chr1 | 6592107 | + | SUPT5H | chr19 | 39960799 | + |
| intron-3CDS | ENST00000377705 | ENST00000598725 | NOL9 | chr1 | 6592107 | + | SUPT5H | chr19 | 39960799 | + |
Top |
FusionProtFeatures for NOL9_SUPT5H |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| NOL9 | SUPT5H |
| Polynucleotide 5'-kinase involved in rRNA processing.The kinase activity is required for the processing of the 32Sprecursor into 5.8S and 28S rRNAs, more specifically for thegeneration of the major 5.8S(S) form. In vitro, has both DNA andRNA 5'-kinase activities. Probably binds RNA.{ECO:0000269|PubMed:21063389}. | Component of the DRB sensitivity-inducing factor complex(DSIF complex), which regulates mRNA processing and transcriptionelongation by RNA polymerase II. DSIF positively regulates mRNAcapping by stimulating the mRNA guanylyltransferase activity ofRNGTT/CAP1A. DSIF also acts cooperatively with the negativeelongation factor complex (NELF complex) to enhancetranscriptional pausing at sites proximal to the promoter.Transcriptional pausing may facilitate the assembly of anelongation competent RNA polymerase II complex. DSIF and NELFpromote pausing by inhibition of the transcription elongationfactor TFIIS/S-II. TFIIS/S-II binds to RNA polymerase II attranscription pause sites and stimulates the weak intrinsicnuclease activity of the enzyme. Cleavage of blocked transcriptsby RNA polymerase II promotes the resumption of transcription fromthe new 3' terminus and may allow repeated attempts attranscription through natural pause sites. DSIF can alsopositively regulate transcriptional elongation and is required forthe efficient activation of transcriptional elongation by the HIV-1 nuclear transcriptional activator, Tat. DSIF acts to suppresstranscriptional pausing in transcripts derived from the HIV-1 LTRand blocks premature release of HIV-1 transcripts at terminatorsequences. {ECO:0000269|PubMed:10075709,ECO:0000269|PubMed:10199401, ECO:0000269|PubMed:10393184,ECO:0000269|PubMed:10421630, ECO:0000269|PubMed:10454543,ECO:0000269|PubMed:10757782, ECO:0000269|PubMed:10912001,ECO:0000269|PubMed:11112772, ECO:0000269|PubMed:11553615,ECO:0000269|PubMed:11809800, ECO:0000269|PubMed:12653964,ECO:0000269|PubMed:12718890, ECO:0000269|PubMed:14701750,ECO:0000269|PubMed:15136722, ECO:0000269|PubMed:15380072,ECO:0000269|PubMed:16214896, ECO:0000269|PubMed:9450929,ECO:0000269|PubMed:9514752, ECO:0000269|PubMed:9857195}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for NOL9_SUPT5H |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for NOL9_SUPT5H |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for NOL9_SUPT5H |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for NOL9_SUPT5H |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|